Effects of systemic injection of a selective dopamine D2-like receptor antagonist, raclopride, on the number, duration, and relative power of HVSs, and the HVS-related coherence of the M1–GP pair.

A: number of HVSs. B: duration of HVSs. C: representative averaged relative power spectral density curve of the M1 cortex (ECoG), and of GP LFP recorded from saline-treated rats (black lines) and raclopride-treated rats (red or blue lines). D: relative power of both the M1 cortex and GP LFP in the frequency bands associated with HVS oscillations. E: averaged coherence curves of the M1–GP pair in the saline-treated rats (black lines) and raclopride-treated rats (red or blue lines). F: coherence values relating to the HVSs. SAL, saline; RAC 1.0, raclopride 1.0 mg/kg; RAC 3.0, raclopride 3.0 mg/kg; HVSs, high-voltage spindles; M1, primary motor cortex; GP, globus pallidus.*P#Significant difference between RAC 1.0 and RAC 3.0.